HC Wainwright Forecasts Strong Price Appreciation for Genmab A/S (NASDAQ:GMAB) Stock

Genmab A/S (NASDAQ:GMAB) had its target price raised by investment analysts at HC Wainwright from $40.00 to $50.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 38.70% from the company’s previous close. HC Wainwright also issued estimates for Genmab A/S’s FY2027 earnings at $1.59 EPS.

Several other analysts have also recently commented on GMAB. TD Cowen upgraded Genmab A/S from a “hold” rating to a “buy” rating and upped their target price for the company from $32.00 to $43.00 in a report on Wednesday, July 22nd. Weiss Ratings upgraded shares of Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday, September 1st. New Street Research set a $43.00 price objective on shares of Genmab A/S in a research report on Wednesday, July 22nd. Finally, Guggenheim lifted their target price on shares of Genmab A/S from $45.00 to $54.00 and gave the stock a “buy” rating in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $42.50.

Genmab A/S Stock Down 1.6%

Shares of NASDAQ:GMAB opened at $36.05 on Wednesday. The firm has a market cap of $22.50 billion, a P/E ratio of 28.39, a P/E/G ratio of 1.69 and a beta of 0.81. The company has a quick ratio of 2.44, a current ratio of 2.46 and a debt-to-equity ratio of 0.81. Genmab A/S has a 12-month low of $23.62 and a 12-month high of $40.17. The business has a fifty day simple moving average of $33.45 and a 200 day simple moving average of $29.30.

Genmab A/S (NASDAQ:GMAB) last announced its earnings results on Thursday, August 6th. The company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.37 by $0.17. The firm had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.12 billion. Genmab A/S had a return on equity of 14.89% and a net margin of 19.08%. Analysts predict that Genmab A/S will post 1.21 earnings per share for the current year.

Institutional Trading of Genmab A/S

Several hedge funds have recently modified their holdings of GMAB. Arrowstreet Capital Limited Partnership grew its stake in shares of Genmab A/S by 36.6% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 4,978,058 shares of the company’s stock valued at $153,324,000 after buying an additional 1,334,919 shares during the period. First Trust Advisors LP raised its stake in Genmab A/S by 84.3% during the 1st quarter. First Trust Advisors LP now owns 2,461,342 shares of the company’s stock worth $66,038,000 after buying an additional 1,126,069 shares during the period. Renaissance Technologies LLC raised its stake in Genmab A/S by 26.4% during the 1st quarter. Renaissance Technologies LLC now owns 4,414,550 shares of the company’s stock worth $118,442,000 after buying an additional 921,700 shares during the period. SummitTX Capital L.P. acquired a new position in Genmab A/S during the 1st quarter worth approximately $2,263,000. Finally, Ishara Investments LP bought a new position in Genmab A/S in the fourth quarter worth approximately $2,156,000. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including its DuoBody and HexaBody platforms, to create therapies designed to engage the immune system, target disease-related proteins and improve treatment outcomes.

Genmab’s portfolio includes products developed through partnerships as well as internally discovered candidates.